Clinical Oncology - Issue 2/2024
Reviews
T. Urban, P. Pokorná, O. Slabý
A. A. Soror, R. Eshagh, M. R. Fahim, A. Jamshidian, G. H. Monfared
M. Švecová, K. Fiedlerová, M. Mareková, K. Dubayová
Original Articles
J. Fínek, M. Vočka, J. Bauer, E. Kubala, K. Zycháčková, M. Šedivá, M. Gharibyar, I. Kocáková, E. Čmuchařová, M. Vaňková
M. Homolová, E. Bojtárová, M. Kováčová, K. Klučková, M. Suchánková, M. Kušíková, M. Mistrík, I. Shawkatová
P. Sorokin, M. Novozhilov, D. Utkin, Z. Abduragimova, I. Dudina, A. Nikiforchin, S. Kulikova
Case Reports
I. Šimková, R. Aiglová, F. Koubek, J. Přeček, J. Látal, E. Buriánková, L. Quinn, L. Henzlová, M. Táborský, H. Švébišová, L. Tučková, B. Melichar
Clinical Oncology
2024 Issue 2
Most read in this issue
- Significance of aberrant DNA methylation for cancer diagnostics and therapy
- Feasibility of implementation of the early tumor shrinkage as a potential predictive marker to daily clinical practice in patients with RAS wild type metastatic colorectal cancer, treated with cetuximab – a non-interventional observational study
- Factors influencing overall survival and GvHD development after allogeneic hematopoietic stem cell transplantation – single centre experience
- Tebentafusp in the treatment of metastatic uveal melanoma – the first patient treated in the Czech Republic